Evidence / Marini et al. · 2008
Genistein at three years in a follow-up subgroup
Selected research. Study type, product relevance and limitations are shown separately.
Editorial study summary
- Study type
- Extension of the randomized, double-blind, placebo-controlled bone-density trial.
- Product relevance
- Ingredient research involving genistein.
- Sample or population
- 138 of the original 389 participants continued (71 genistein, 67 placebo).
- Studied dose
- 54 mg/day of genistein aglycone or placebo. Both groups received calcium and vitamin D3.
- Duration
- 36 months in total, including a one-year extension.
- Finding
- Bone density remained higher with genistein. The study did not detect significant changes in mammographic density or endometrial thickness, and reported no between-group difference in discomfort or adverse events.
- Limitations
- This was a selected subset of the same cohort. Imaging and biomarker findings do not establish long-term breast or endometrial safety or fracture prevention.
- Study quality
- The outcomes, study design and limitations were reviewed. No formal risk-of-bias rating was assigned for this summary.
- Funding and disclosures
- The paper reports support from the Italian Ministry of Education, University and Research and Primus Pharmaceuticals, and discloses employment ties for two authors.
The studies discussed here examine ingredients or other formulations. They do not establish results for this DR.MORGAN finished product.
Licensed product information
S-EQUOL PLUS · NPN 80143622
May reduce severe and frequent menopausal symptoms (such as hot flashes and/or night sweats).